US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Dare Bioscience Inc (DARE)
Dare Bioscience Inc (DARE) ニュース

DARE

Dare Bioscience (DARE)

Dare Bioscience Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:DARE

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	05 : 01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:DARE	Dare Bioscience Inc
2024/05/14	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DARE	Dare Bioscience Inc
2024/05/14	21 : 00	GlobeNewswire Inc.	Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update	NASDAQ:DARE	Dare Bioscience Inc
2024/05/13	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:DARE	Dare Bioscience Inc
2024/05/11	05 : 12	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:DARE	Dare Bioscience Inc
2024/05/07	21 : 00	GlobeNewswire Inc.	Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024	NASDAQ:DARE	Dare Bioscience Inc
2024/05/02	21 : 00	GlobeNewswire Inc.	Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network	NASDAQ:DARE	Dare Bioscience Inc
2024/04/30	20 : 30	GlobeNewswire Inc.	Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts	NASDAQ:DARE	Dare Bioscience Inc
2024/04/23	21 : 00	GlobeNewswire Inc.	Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	NASDAQ:DARE	Dare Bioscience Inc
2024/04/11	21 : 00	GlobeNewswire Inc.	Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive	NASDAQ:DARE	Dare Bioscience Inc
2024/03/28	21 : 00	GlobeNewswire Inc.	Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update	NASDAQ:DARE	Dare Bioscience Inc
2024/03/28	20 : 42	IH Market News	US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise	NASDAQ:DARE	Dare Bioscience Inc
2024/03/21	21 : 00	GlobeNewswire Inc.	Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024	NASDAQ:DARE	Dare Bioscience Inc
2024/02/22	22 : 00	GlobeNewswire Inc.	Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting	NASDAQ:DARE	Dare Bioscience Inc
2024/01/31	22 : 00	GlobeNewswire Inc.	Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	NASDAQ:DARE	Dare Bioscience Inc
2024/01/30	06 : 18	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:DARE	Dare Bioscience Inc
2024/01/27	07 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DARE	Dare Bioscience Inc
2024/01/27	06 : 30	GlobeNewswire Inc.	Daré Bioscience Announces Executive Team and Board of Directors Changes	NASDAQ:DARE	Dare Bioscience Inc
2024/01/20	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DARE	Dare Bioscience Inc
2024/01/17	22 : 00	GlobeNewswire Inc.	Daré Bioscience Announces Grant to Support Biotherapeutic Product Development	NASDAQ:DARE	Dare Bioscience Inc
2024/01/08	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DARE	Dare Bioscience Inc
2024/01/04	22 : 00	GlobeNewswire Inc.	Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases	NASDAQ:DARE	Dare Bioscience Inc
2023/12/27	06 : 05	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:DARE	Dare Bioscience Inc
2023/12/26	22 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DARE	Dare Bioscience Inc
2023/12/26	22 : 00	GlobeNewswire Inc.	Daré Bioscience Secures $12 million in Royalty-backed Investment Structure	NASDAQ:DARE	Dare Bioscience Inc
2023/12/20	22 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DARE	Dare Bioscience Inc
2023/12/20	22 : 00	GlobeNewswire Inc.	Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study	NASDAQ:DARE	Dare Bioscience Inc
2023/12/13	22 : 00	GlobeNewswire Inc.	Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study	NASDAQ:DARE	Dare Bioscience Inc
2023/12/07	22 : 00	GlobeNewswire Inc.	Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause	NASDAQ:DARE	Dare Bioscience Inc
2023/12/04	22 : 00	GlobeNewswire Inc.	Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive	NASDAQ:DARE	Dare Bioscience Inc

Showing the most relevant articles for your search:NASDAQ:DARE

1 2 3 4 5 6 7 8 9 10 次へ >>

JP Morgan Chase

US Dollar vs Euro

Verizon Communications

US Dollar vs Yen

Gold vs US Dollar

Deutsche Telekom (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約